Manualised cognitive–behavioural therapy in treating depression in advanced cancer: the CanTalk RCT

Marc Serfaty,1,2* Michael King,1,3 Irwin Nazareth,3 Stirling Moorey,4,5 Trefor Aspden,1 Adrian Tookman,6 Kathryn Mannix,7 Anna Gola,3,8 Sarah Davis,1,7 John Wood3 and Louise Jones1,6

1Division of Psychiatry, University College London, London, UK
2Priory Hospital North London, London, UK
3Research Department of Primary Care & Population Health, University College London, London, UK
4South London and Maudsley NHS Foundation Trust, London, UK
5Institute of Psychiatry, Psychology and Neuroscience, King’s College London, London, UK
6Marie Curie Hospice, Royal Free Hampstead NHS Trust, London, UK
7Palliative Care Service, Newcastle upon Tyne Hospital NHS Foundation Trust, Newcastle upon Tyne, UK
8Marie Curie Palliative Care Research Department, University College London, London, UK

*Corresponding author m.serfaty@ucl.ac.uk

Declared competing interests of authors: Marc Serfaty is a member of the National Institute for Health Research Health Technology Assessment General Board.

Published May 2019
DOI: 10.3310/hta23190

Scientific summary

The CanTalk RCT
Health Technology Assessment 2019; Vol. 23: No. 19
DOI: 10.3310/hta23190

NIHR Journals Library www.journalslibrary.nihr.ac.uk
Scientific summary

Background

The CanTalk trial was a randomised controlled trial (RCT) testing the clinical effectiveness and cost-effectiveness of cognitive–behavioural therapy (CBT) for depression in ‘advanced cancer’, defined as cancer that is not amenable to cure or cancer in people with metastatic disease for whom standard curative therapies have failed and/or in those with a poor prognosis.

A meta-analysis of depression in advanced cancer suggested the prevalence of clinical depression to be 16.5%. There is a considerable economic cost associated with depression, and individuals with cancer and depression face several negative health outcomes.

An updated Cochrane review has considered which psychosocial therapies are effective in advanced cancer and depression (Akechi T, Okuyama T, Onishi J, Morita T, Furukawa TA. Psychotherapy for depression among incurable cancer patients. Cochrane Database Syst Rev 2008;2:CD005537). A recent review suggested that CBT appeared to be the most promising. CBT challenges negative ways of thinking and unhelpful ways of behaving by teaching the individual to challenge and modify negative thoughts and unhelpful behaviours to help improve mood.

Currently, the UK agenda for treating depression aims to widen access to psychological treatment delivered in primary care by trained mental health practitioners attached to the Improving Access to Psychological Therapies (IAPT) programme.

As RCTs are the gold standard in research, we chose a parallel RCT design comparing treatment as usual (TAU) with TAU plus the addition of individual manualised CBT for treating depression in advanced cancer.

Stirling Moorey, Kathryn Mannix and Marc Serfaty (co-applicants) developed a treatment manual and a training package for IAPT therapists and supervisors on how to apply their CBT skills to people with advanced cancer.

The revised Consolidated Standards of Reporting Trials guidelines for reporting non-pharmacological trials recommend that a description of different components of the intervention is provided when evaluating non-pharmacological interventions. It is recommended that three measures are recorded to evaluate treatment implementation: (1) delivery, (2) receipt and (3) enactment. We used mixed methods to record all measures except enactment.

Objectives

To conduct a RCT to test the clinical effectiveness and cost-effectiveness of TAU compared with TAU plus individual CBT (delivered through IAPT) for treating depressive symptoms in people with advanced cancer.

Methods

Design
Parallel-group RCT.
Participants
Patients (n = 230) with advanced cancer and depression.

Inclusion criteria
- Diagnosis of cancer not amenable to cure.
- A Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition diagnosis of depressive disorder using the Mini-International Neuropsychiatric Interview (MINI).
- Sufficient understanding of English.
- Eligibility for treatment in an IAPT centre.

Exclusion criteria
- Clinician-estimated survival of < 4 months.
- High suicide risk established using the MINI.
- Currently receiving, or having received in the last 2 months, a psychological intervention recommended by the National Institute for Health and Care Excellence (NICE) for treating depression.

Setting
Participants were recruited from oncology centres, general practitioner practices, a local hospice and through self-referral.

Randomisation
Participants were randomised 1 : 1 to TAU or TAU plus CBT using Sealed Envelope™ (Sealed Envelope Ltd, London, UK), a web-based system. Randomisation was conducted using permuted blocks with sizes of four or six, stratified for antidepressant usage (yes/no).

Masking
Researchers and Primary Care Research Network assessors were blinded to group allocation.

Interventions
Treatment as usual
All participants received TAU from clinicians involved in their care.

Cognitive–behavioural therapy (in addition to treatment as usual)
Cognitive–behavioural therapy was delivered by high-level British Association for Behavioural and Cognitive Psychotherapies-accredited IAPT therapists. The intervention comprised up to 12 sessions of individual, manualised CBT delivered either face to face or over the telephone over 3 months. These sessions are outlined below:

- session 1 – assessing and introducing the cognitive–behavioural model
- session 2 – developing an understanding of problems within a cognitive framework
- session 3 – reviewing the formulation, identifying new insights/changes through guided discovery. Identifying helpful versus ‘unhelpful’ thinking
- sessions 4–5 – reformulating success experiences, identifying triggers and developing new coping strategies through guided discovery
- session 6–7 – challenging thoughts and generating alternative ‘helpful’ ways of thinking
- session 8 – problem solving, checking that concepts are understood and realistic concerns addressed along with introducing ‘worry time’
- session 9 – consolidating CBT strategies, prioritising problems and using worry management strategies
- session 10 – reviewing progress
• session 11 – conducting relapse prevention through reviewing difficulties, identifying achievements and promoting personal resilience
• session 12 – future planning by creating relapse prevention checklists and planning for action if distress or unhelpful behaviours/thinking recurs.

**Training**
Improving Access to Psychological Therapies therapists were given a day’s training by the CanTalk team (SM, MS and KM) to help apply existing CBT skills to people with advanced cancer.

**Location of therapy**
Therapy was offered at the local IAPT centre or by telephone CBT for those who had seen the therapist at least three times.

**Assessment of delivery of cognitive–behavioural therapy**
Delivery of CBT was assessed using the Cognitive Therapy Scale – Revised (CTS-R) and through qualitative interviews.

**Qualitative methods**
Three embedded qualitative studies were included:

1. clinicians’ experiences of referring into the CanTalk trial
2. therapists’ experiences of delivering CBT
3. patients’ experiences of CBT.

**Primary outcome**

• Beck Depression Inventory, version 2 (BDI-II): a 21-item self-report measure with a maximum score of 63 points.

**Secondary outcomes**

• Patient Health Questionnaire-9 (PHQ-9): a nine-item measure validated as a measure of depression in primary care.
• EuroQol-5 Dimensions (EQ-5D): a generic utility measure of quality of life.
• Satisfaction with care: a five-item scale.
• Eastern Cooperative Oncology Group Performance Status (ECOG-PS): a measure of physical functioning.
• Client Service Receipt Inventory (CSRI): a short, modified CSRI that collects data on service use.

**Timing of measures**
The BDI-II, PHQ-9, EQ-5D, ECOG-PS and CSRI were collected at baseline, 12 and 24 weeks. The BDI-II was also collected at 6 and 18 weeks.

**Sample size**
Our primary outcome was an overall effect of treatment over the 24 weeks. The power was to enable a detection of a difference in BDI-II of 6 points [standard deviation (SD) 12 points] between the TAU and CBT groups measured at 12 weeks, assuming a treatment effect of 3 points after 6 weeks and a sustained 6-point difference after 18 and 24 weeks. We assumed a 70% follow-up at 6 weeks, decreasing to 65% at 12 weeks and 60% at 24 weeks.

The correlation between BDI-II values from sessions 1 week apart is reported as 0.93. We estimated the correlation between measures taken 6 weeks apart to be $0.935 = 0.65$. 
Sample size calculations estimated that, at 90% power and 5% significance, 109 participants were required per trial arm. This was inflated by a factor of 1.10 to allow for therapist clustering, giving 120 participants per trial arm.

**Analysis**

**Clinical outcomes**

The primary analysis was a comparison on an intention-to-treat basis between the CBT and control arms for the BDI-II score measured at 6, 12, 18 and 24 weeks using multilevel modelling, allowing for repeated measurements with equal weighting for each time point, adjusting for therapist clustering. The model comprised three levels: (1) repeated measures, (2) individuals and (3) therapists. Baseline BDI-II score and antidepressant use were included as fixed effects. The model was fitted using a linear mixed-effects model assuming a Gaussian error distribution.

Supportive analysis included the primary analysis, which was repeated (1) using clustering by IAPT service, (2) ignoring clustering, (3) including additional covariates and (4) with separate analyses carried out for each follow-up point. Exploratory and subgroup analysis included the primary analysis in addition to (1) a treatment by time interaction, (2) a treatment by marital status interaction and (3) a treatment by education status interaction. We also conducted a contamination-adjusted intention-to-treat (CAITT) analysis using the 18- and/or 24-week total BDI-II score.

For the secondary outcomes of PHQ-9 and satisfaction with care, we used a similar approach to the primary analysis.

**Cost-effectiveness**

Quality-adjusted life-years (QALYs) were calculated from EQ-5D scores at baseline, 12 and 24 weeks’ follow-up. Service use costs were calculated from resource data to calculate the total cost of resources used by each study participant.

Costs were compared for the groups using a bootstrap regression model to account for non-normality in the distribution of cost data. A cost–utility analysis was undertaken using QALYs calculated from the EQ-5D measure. Cost-effectiveness was assessed by estimating an incremental cost-effectiveness ratio (ICER) to show the extra cost incurred by CBT to generate one extra QALY. To deal with uncertainty around the ICER, a cost-effectiveness plane (CEP) and cost-effectiveness acceptability curves (CEACs) were created.

**Qualitative data**

Semistructured interviews were conducted and transcribed. Data were analysed using thematic content analysis.

**Results**

**Recruitment and follow-up**

We screened 2224 patients with advanced cancer. Of those, 819 did not meet the inclusion criteria, 1021 declined to participate, 144 were excluded for reasons not recorded and 240 participants were referred for baseline. Of the 240 patients referred for baseline, 230 consented to participate and were randomised.

Participants were predominantly female (66%) and of white ethnicity (73%) with a mean age of 59.5 years. Two-thirds of patients had tumours in one of the five main groups: (1) breast, (2) colorectal, (3) lung, (4) prostate and (5) haematological. A total of 60% of participants had a previous history of depression.
Over the follow-up period, 37 participants in the CBT group and 25 participants in the TAU group died or withdrew from the study. The number of participants with at least one follow-up point was 93 in the CBT group and 92 in the TAU group.

Clinical outcomes
The primary analysis of the BDI-II score did not find a significant benefit of CBT plus TAU versus TAU alone [treatment effect $-0.84$, 95% confidence interval (CI) $-2.755$ to $1.083$; $p = 0.39$]. Subsidiary analysis also showed no benefit of CBT over TAU. Out of the exploratory analysis, in our predetermined analysis plan, marital status demonstrated a benefit for CBT plus TAU over TAU alone for participants who were widowed, divorced or separated (treatment effect $-7.21$, 95% CI $-11.15$ to $-3.28$; $p < 0.001$).

For the CAITT analysis, 153 participants were included. The estimated ‘per-session’ effect on the BDI-II was $-0.30$ points (95% CI $-0.76$ to $0.17$ points; $p = 0.21$).

Similar to the BDI-II, PHQ-9 scores and satisfaction with care scores showed a lack of significant benefit for CBT plus TAU compared with TAU alone.

Eastern Cooperative Oncology Group Performance Status scores were similar throughout the study, with around one-fifth of participants being fully active and two-fifths being of restricted mobility. Overall satisfaction with care was around 80%.

Cost-effectiveness
At baseline, 12 and 24 weeks, there were no significant differences in service use (excluding CBT) between TAU and TAU plus CBT. The mean service costs for participants (not including the costs of the interventions) were similar across the two groups.

There were no differences in EQ-5D median scores at baseline, nor was there any advantage of CBT over TAU at 12 weeks or 24 weeks. There was no statistically significant improvement in QALYs at 24 weeks.

The CEP indicates a 15.5% chance that CBT is cheaper and produces more QALYs, and a 74% chance that CBT is more expensive and produces more QALYs. The CEAC indicates that, at the NICE threshold, the probability of CBT being effective is 52%.

Intervention
A total of 543 (39.3%) sessions out of a potential total of 1380 were taken up, of which 32 (5.9%) were by telephone. The mean time from being referred to being seen by an IAPT therapist was 29.4 days (SD 26.7 days). For participants randomised to CBT, the mean number of sessions received was 4.7 (SD 4.9) and 41 participants (35.6%) did not take up any sessions.

Of the 543 therapy sessions delivered, 55 tapes (1 in 10) were rated. The mean CTS-R score by phase of therapy was 47.9 points (SD 10.6 points) for 21 early sessions, 48.1 points (SD 18.8 points) for 19 middle sessions and 46.7 points (SD 10.9 points) for 15 late sessions, indicating strong adherence to the therapeutic model in CBT.

Guided discovery, activity scheduling, discussion about specific cancer topics, covering the impact of the physical illness and beliefs and expectations about the illness were most the most common interventions.

Qualitative findings
Health-care workers’ views about the CanTalk trial
This substudy asked 14 health-care workers about their views of psychological (non-pharmaceutical) research. Themes included recruitment issues – finding time and money, competing interests, catchment area limits; the role of the clinician – their influence on the team, patient participation and trying to protect
patients; the sensitive nature of the research – clashes with existing services and concerns regarding people not eligible for the trial; and concerns about the trial team mis-selling research to units but wanting the trial team to be involved in recruiting.

**Therapists’ views of treating patients with advanced cancer**

Sixteen therapists were interviewed using semistructured interviews. Themes included knowledge of cancer – would have liked more knowledge, but gained this from talking to the patient; experience of training – would have liked more information about type of cancer; concerns about treating advanced cancer patients – anxiety about treating cancer patients, but surprise at how receptive patients were; supervision – would have liked more specialist support; experience of working with patients – generally easy to co-ordinate meetings and experience more positive than expected; and therapy materials – therapists generally liked the materials, but it was not always easy to adhere to the manual.

**Patients’ views about cognitive–behavioural therapy**

Interviews were conducted with 10 patients who had received CBT. Themes included expectations and knowledge of CBT – some knowledge, but little experience of CBT; structure and delivery of CBT – service location was convenient, but transport could be a barrier; experience of CBT – CBT was helpful, facilitated their ability to talk about cancer and to deal with unhelpful thinking; and other therapeutic options for advanced cancer patients – it was felt that CBT would not be for everyone and that therapy should be tailored to the needs of the patient. Suggested improvements included offering therapy in hospital, a manual/workbook for patients, therapy for carers and reducing the frequency of sessions.

**Discussion**

In this sufficiently powered trial, CBT delivered through IAPT was not clinically effective or cost-effective for treating depression in those with advanced cancer, despite the quality of therapy delivered being high and the uptake consistent with the number of sessions taken up through IAPT. However, CBT was clinically effective for those widowed, divorced or separated and this is consistent with data on the use of CBT to treat depression in the community.

**Conclusions**

Cognitive–behavioural therapy delivered through IAPT is not recommended for treating depression in people with advanced cancer, although a subgroup of those who are widowed, divorced or separated may benefit from screening and referral to IAPT for CBT. Alternative research evaluating integrative care models for treating depression in people with a range of cancers is worth testing. It remains to be established whether or not mechanisms of change in our widowed, divorced or separated population was associated with specific or non-specific treatment effect.

**Trial registration**

The trial is registered as ISRCTN07622709.

**Funding**

Funding for this study was provided by the Health Technology Assessment programme of the National Institute for Health Research.
Health Technology Assessment

ISSN 1366-5278 (Print)
ISSN 2046-4924 (Online)
Impact factor: 4.513

Health Technology Assessment is indexed in MEDLINE, CINAHL, EMBASE, The Cochrane Library and the Clarivate Analytics Science Citation Index.

This journal is a member of and subscribes to the principles of the Committee on Publication Ethics (COPE) (www.publicationethics.org/).

Editorial contact: journals.library@nihr.ac.uk

The full HTA archive is freely available to view online at www.journalslibrary.nihr.ac.uk/hta. Print-on-demand copies can be purchased from the report pages of the NIHR Journals Library website: www.journalslibrary.nihr.ac.uk

Criteria for inclusion in the Health Technology Assessment journal

Reports are published in Health Technology Assessment (HTA) if (1) they have resulted from work for the HTA programme, and (2) they are of a sufficiently high scientific quality as assessed by the reviewers and editors.

Reviews in Health Technology Assessment are termed ‘systematic’ when the account of the search appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

HTA programme

The HTA programme, part of the National Institute for Health Research (NIHR), was set up in 1993. It produces high-quality research information on the effectiveness, costs and broader impact of health technologies for those who use, manage and provide care in the NHS. ‘Health technologies’ are broadly defined as all interventions used to promote health, prevent and treat disease, and improve rehabilitation and long-term care.

The journal is indexed in NHS Evidence via its abstracts included in MEDLINE and its Technology Assessment Reports inform National Institute for Health and Care Excellence (NICE) guidance. HTA research is also an important source of evidence for National Screening Committee (NSC) policy decisions.

For more information about the HTA programme please visit the website: http://www.nets.nihr.ac.uk/programmes/hta

This report

The research reported in this issue of the journal was funded by the HTA programme as project number 09/33/02. The contractual start date was in March 2012. The draft report began editorial review in May 2017 and was accepted for publication in January 2018. The authors have been wholly responsible for all data collection, analysis and interpretation, and for writing up their work. The HTA editors and publisher have tried to ensure the accuracy of the authors’ report and would like to thank the reviewers for their constructive comments on the draft document. However, they do not accept liability for damages or losses arising from material published in this report.

This report presents independent research funded by the National Institute for Health Research (NIHR). The views and opinions expressed by authors in this publication are those of the authors and do not necessarily reflect those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care. If there are verbatim quotations included in this publication the views and opinions expressed by the interviewees are those of the interviewees and do not necessarily reflect those of the authors, those of the NHS, the NIHR, NETSCC, the HTA programme or the Department of Health and Social Care.

© Queen’s Printer and Controller of HMSO 2019. This work was produced by Serfaty et al. under the terms of a commissioning contract issued by the Secretary of State for Health and Social Care. This issue may be freely reproduced for the purposes of private research and study and extracts (or indeed, the full report) may be included in professional journals provided that suitable acknowledgement is made and the reproduction is not associated with any form of advertising. Applications for commercial reproduction should be addressed to: NIHR Journals Library, National Institute for Health Research, Evaluation, Trials and Studies Coordinating Centre, Alpha House, University of Southampton Science Park, Southampton SO16 7NS, UK.

Published by the NIHR Journals Library (www.journalslibrary.nihr.ac.uk), produced by Prepress Projects Ltd, Perth, Scotland (www.prepress-projects.co.uk).
NIHR Journals Library Editor-in-Chief

Professor Ken Stein  Professor of Public Health, University of Exeter Medical School, UK

NIHR Journals Library Editors

Professor John Powell  Chair of HTA and EME Editorial Board and Editor-in-Chief of HTA and EME journals. Consultant Clinical Adviser, National Institute for Health and Care Excellence (NICE), UK, and Honorary Professor, University of Manchester, and Senior Clinical Researcher and Associate Professor, Nuffield Department of Primary Care Health Sciences, University of Oxford, UK

Professor Andrée Le May  Chair of NIHR Journals Library Editorial Group (HS&DR, PGfAR, PHR journals) and Editor-in-Chief of HS&DR, PGfAR, PHR journals

Professor Matthias Beck  Professor of Management, Cork University Business School, Department of Management and Marketing, University College Cork, Ireland

Dr Tessa Crilly  Director, Crystal Blue Consulting Ltd, UK

Dr Eugenia Cronin  Senior Scientific Advisor, Wessex Institute, UK

Dr Peter Davidson  Consultant Advisor, Wessex Institute, University of Southampton, UK

Ms Tara Lamont  Director, NIHR Dissemination Centre, UK

Dr Catriona McDaid  Senior Research Fellow, York Trials Unit, Department of Health Sciences, University of York, UK

Professor William McGuire  Professor of Child Health, Hull York Medical School, University of York, UK

Professor Geoffrey Meads  Professor of Wellbeing Research, University of Winchester, UK

Professor John Norrie  Chair in Medical Statistics, University of Edinburgh, UK

Professor James Raftery  Professor of Health Technology Assessment, Wessex Institute, Faculty of Medicine, University of Southampton, UK

Dr Rob Riemsma  Reviews Manager, Kleijnen Systematic Reviews Ltd, UK

Professor Helen Roberts  Professor of Child Health Research, UCL Great Ormond Street Institute of Child Health, UK

Professor Jonathan Ross  Professor of Sexual Health and HIV, University Hospital Birmingham, UK

Professor Helen Snooks  Professor of Health Services Research, Institute of Life Science, College of Medicine, Swansea University, UK

Professor Ken Stein  Professor of Public Health, University of Exeter Medical School, UK

Professor Jim Thornton  Professor of Obstetrics and Gynaecology, Faculty of Medicine and Health Sciences, University of Nottingham, UK

Professor Martin Underwood  Warwick Clinical Trials Unit, Warwick Medical School, University of Warwick, UK

Please visit the website for a list of editors: www.journalslibrary.nihr.ac.uk/about/editors

Editorial contact: journals.library@nihr.ac.uk